Why It Matters

Soter Bio LLC’s federal lobbying debut positions the company to influence rapidly expanding biosecurity policy. Congress is actively legislating on biodefense supply chains through bills like H.R.5186, which authorizes DoD investment in biosecurity infrastructure—precisely what Soter Bio offers. The company’s focus on "addressing supply chain issues and operational readiness" aligns with bipartisan momentum, including the Promoting Resilient Supply Chains Act and heightened attention to biosafety compliance.

By the Numbers

Soter Bio retained Tenagrity Solutions LLC as its sole lobbying firm, with Jenny Caroline DeBerry as the sole registered lobbyist.

Tenagrity Solutions brings specialized experience directly aligned with Soter Bio’s objectives, with concentrated focus on Defense (32 instances) and Health Issues (36 instances). The firm’s client roster demonstrates niche expertise:

DeBerry served as Legislative Assistant to Rep. John Duncan (R-TN-2) from 2015–2019, providing Republican House relationships. Her lobbying portfolio shows consistent work on healthcare-defense intersections, representing biotech companies before DoD and HHS officials.

The Agenda

The new client registration filed in December 2024 reveals Soter Bio’s strategy to "raise awareness of the company’s capabilities and potential to address supply chain issues and operational readiness."

Congress has elevated biotech supply chains to a national security priority. The FY 2026 National Defense Authorization Act included 17 new biotechnology provisions, and the BIOSECURE Act restricting federal procurement from foreign biotech companies was incorporated into the NDAA. Multiple bills advance this agenda, including:

  • H.R. 5186 authorizing DoD investment in biotechnology supply chain infrastructure
  • S. 257 / H.R. 2444 establishing a government-wide working group on supply chain vulnerabilities
  • H.R. 5747 mandating tracking of highly pathogenic agents

Geopolitical competition amplifies congressional urgency. The ongoing H5N1 outbreak—with 71 U.S. cases since March 2024—has exposed pandemic preparedness vulnerabilities. President Trump’s executive order establishing a Strategic Active Pharmaceutical Ingredients Reserve reinforces executive-branch commitment to supply chain resilience.

Between The Lines

A House Armed Services Subcommittee hearing in March 2025 featured testimony on biomanufacturing capabilities and supply chain resilience. The newly formed Bipartisan BIOTech Caucus led by Representatives Chrissy Houlahan (D-PA) and Stephanie Bice (R-OK) focuses on domestic biosecurity. Meanwhile, Senator Kirsten Gillibrand (D-NY) has championed $2.5 million in funding for high-containment laboratory infrastructure, demonstrating sustained bipartisan support.

What distinguishes Soter Bio’s positioning is its specialized focus on biosafety operations and supply chain resilience. While other health-tech firms compete for defense contracts generally, few specialize in the operational aspects of high-containment laboratory facilities.

The Bottom Line

Soter Bio LLC launched federal lobbying at an opportune moment for biosecurity advocacy. Congress is actively advancing biodefense legislation, including provisions restricting foreign biotech procurement and funding domestic manufacturing. Rising H5N1 cases, executive orders on pharmaceutical supply chains, and U.S.-China competition in biotechnology create policy demand for Soter Bio’s expertise. The company faces a favorable legislative environment with the newly formed bipartisan BIOTech Caucus and active congressional committee focus on biodefense providing direct engagement opportunities.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article